Smith & Nephew (NYSE:SNN) Upgraded to “Strong-Buy” at StockNews.com

StockNews.com upgraded shares of Smith & Nephew (NYSE:SNN) from a buy rating to a strong-buy rating in a report issued on Monday morning.

A number of other equities research analysts have also recently weighed in on the company. UBS Group upgraded shares of Smith & Nephew from a neutral rating to a buy rating in a research note on Wednesday, June 5th. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Smith & Nephew in a research note on Wednesday, July 24th. They set a buy rating on the stock. Two investment analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Smith & Nephew has an average rating of Moderate Buy.

Smith & Nephew Stock Performance

SNN opened at $30.17 on Monday. The business’s 50 day moving average is $27.01 and its 200-day moving average is $26.47. The company has a quick ratio of 0.72, a current ratio of 1.77 and a debt-to-equity ratio of 0.44. Smith & Nephew has a twelve month low of $21.52 and a twelve month high of $31.13.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Inspire Advisors LLC grew its position in Smith & Nephew by 3.0% in the second quarter. Inspire Advisors LLC now owns 22,286 shares of the medical equipment provider’s stock worth $552,000 after buying an additional 639 shares during the last quarter. Oppenheimer Asset Management Inc. grew its position in Smith & Nephew by 41.0% in the second quarter. Oppenheimer Asset Management Inc. now owns 16,298 shares of the medical equipment provider’s stock worth $404,000 after buying an additional 4,743 shares during the last quarter. Equity Investment Corp grew its position in Smith & Nephew by 27.3% in the second quarter. Equity Investment Corp now owns 14,921 shares of the medical equipment provider’s stock worth $370,000 after buying an additional 3,200 shares during the last quarter. American Century Companies Inc. grew its position in Smith & Nephew by 9.3% in the second quarter. American Century Companies Inc. now owns 119,347 shares of the medical equipment provider’s stock worth $2,957,000 after buying an additional 10,156 shares during the last quarter. Finally, Rhumbline Advisers grew its position in Smith & Nephew by 8.6% in the second quarter. Rhumbline Advisers now owns 10,365 shares of the medical equipment provider’s stock worth $257,000 after buying an additional 819 shares during the last quarter. Institutional investors and hedge funds own 25.64% of the company’s stock.

About Smith & Nephew

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.